Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
Figure 2
Therapy with the HER-2-redirected oncolytic HSV, R-LM249, of nude mice bearing i.p. human SK-OV-3 ovarian carcinoma.
Red arrows below x-axis mark the days in which groups of 5 mice received weekly i.p. treatments with R-LM249 (2×107 p.f.u./treatment) or vehicle (PBS). Significance of curve comparison: p = 0.02 by the Mantel-Haenszel test.